Gokhan Sahin

Ege, 35100, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.

Journal: Journal of clinical medicine

Published: June 24, 2026

Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.

Journal: Medicina (Kaunas, Lithuania)

Published: June 08, 2026

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Journal: Expert review of clinical immunology

Published: June 03, 2026

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Journal: Immunotherapy

Published: April 20, 2026

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Journal: Expert review of anticancer therapy

Published: January 08, 2026

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Journal: Expert review of anticancer therapy

Published: December 10, 2025

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Journal: Frontiers in oncology

Published: November 28, 2025

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 14, 2025

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Journal: BMC cancer

Published: October 02, 2025

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Journal: Journal of chemotherapy (Florence, Italy)

Published: September 11, 2025

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Journal: International journal of cancer

Published: August 13, 2025

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.

Journal: International journal of cancer

Published: July 31, 2025

Showing 1-12 of 32

Last Updated: 09/26/2026